All In Biotech

Drug Trial Radar · NCT07718737

Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Open-Label, Global, Multicenter, Randomized, Phase 2/3 Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 512 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

512

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Mar 30, 2028

Study completion Dec 30, 2028

Sponsor

Lead sponsor
Multitude Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jul 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial consists of two parts: phase 2 and phase 3. The goal of phase 2 of this clinical trial is to compare which dose level of AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype non-small cell lung cancer (NSCLC) in adults. It will also learn about the safety of AMT-116. The main questions it aims to answer are: * Which level of AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype NSCLC? * What medical problems do participants have when taking AMT-116? The goal of phase 3 of this clinical trial is to compare AMT-116 to study doctor's choice (a kind of retainable treatment for you in the opinion of the study doctor) to see if AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype NSCLC. In both parts of this trial, participants will receive AMT-116 or study doctor's choice every 2 weeks until the study doctor thinks you are benefiting from your participation or until your disease progresses or you are unable to tolerate the study drug

Conditions

  • NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

  • AMT-116Drug

    AMT-116 will be administered at 4 mg/kg or 5 mg/kg as an intravenous (IV) infusion on Day 1 of each 2-week cycle.

  • Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab)Drug

    Docetaxel will be administered as an IV infusion of 75 mg/m2 over approximately 60 minutes on Day 1 of each 3-week cycle. Ramucirumab will be administered as an IV infusion of 10 mg/kg over 30-60 minutes on Day 1 of each 3-week cycle prior to docetaxel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events as Assessed by CTCAE v6.0Time frame: About 7 months

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Hematology Oncology Associates of the Treasure Coast

    Port Saint Lucie, Florida · Not yet recruiting

  • Lumi Research

    Kingwood, Texas · Not yet recruiting

  • Coffs Harbour Health Campus

    Coffs Harbour, Australia · Not yet recruiting

  • Austin Health (Olivia Newton John Cancer Centre)

    Melbourne, Australia · Not yet recruiting

  • St Vincent's Hospital Melbourne

    Melbourne, Australia · Not yet recruiting

  • Calvary Mater Newcastle

    Newcastle, Australia · Not yet recruiting

  • Macquarie University Hospital

    Sydney, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.